EBT

Services & Partnering

Large & Mid-Size Pharma

De-prioritized assets already registered in Europe/ex-Europe

Small Biotech

Novel launch assets not yet registered in Europe; EU license holders

Chinese Biotech

Novel launch assets not yet registered in Europe; EU license holders

ScopeEBT’s Scope of Services Focused on Maximizing Patient Access & Asset Value

Overview of EBT’s comprehensive services:

  • Product launch planning and execution
  • Promotional and marketing activities to create market awareness
  • Medical affairs and KOL management to engage healthcare professionals
  • Supply chain distribution and fulfilment to ensure product availability
  • Pharmacovigilance and regulatory compliance to adhere to all requirement
  • Pricing and reimbursement strategies for optimal market access
  • Full commercialization support to maximize asset value across Europe

Supply Management

Through close collaboration with local stakeholders and well-established distribution networks, EBT safeguards the availability of assets while minimizing the impact of supply risk

Compliance/Pharmacovigilance

EBT ensures full compliance with pharmacovigilance and/or stipulated RMP’s as outlined by regulatory authorities

BIOPHARMABenefits of Partnering with European Biopharma Therapeutics

  • Providing deep regional & market knowledge coupled with solid therapeutic launch experience
  • Minimizing the time and resources needed to invest in a transaction
  • Providing flexibility on deal structure: acquisition, licensing or co-promotion
  • Offering exclusive product focus resulting in near-and long-term result
  • Safeguarding against commercial, medical, legal and reputational risk
  • Advancement of company reputation through ethical and compliant communication/partnership with:
    • Regulators and reimbursement authorities
    • KOL’s/physicians and patients/patient organizations
    • Policymakers and professional societies, etc.
  • Commitment to expanding access to innovation in developing countries through several channels:
    • Regulatory approval and national reimbursement
    • Named-patient and compassionate use/donation program (as appropriate)
    • Comprehensive diagnostic testing support program & diagnostic company partnerships
  • Shared financial upside
  • Potential to leverage our digital infrastructure for partnerships on additional products
  • Opportunity to establish permanent footprint in specific markets (or regions)